<?xml version='1.0' encoding='utf-8'?>
<document id="19850672"><sentence text="Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases."><entity charOffset="54-63" id="DDI-PubMed.19850672.s1.e0" text="erlotinib" /><entity charOffset="68-77" id="DDI-PubMed.19850672.s1.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.19850672.s1.e0" e2="DDI-PubMed.19850672.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19850672.s1.e0" e2="DDI-PubMed.19850672.s1.e1" /></sentence><sentence text="We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-glucuronosyltransferase (UGT) activities and to quantitatively evaluate their drug-drug interaction (DDI) potential due to UGT inhibition"><entity charOffset="51-60" id="DDI-PubMed.19850672.s2.e0" text="erlotinib" /><entity charOffset="65-74" id="DDI-PubMed.19850672.s2.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.19850672.s2.e0" e2="DDI-PubMed.19850672.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19850672.s2.e0" e2="DDI-PubMed.19850672.s2.e1" /></sentence><sentence text=" The inhibitory effects of erlotinib and gefitinib on UGTs were determined using high-performance liquid chromatography by measuring the formation rates for 4-methylumbelliferone (4-MU) glucuronide, imipramine N-glucuronide, and bilirubin glucuronides using recombinant human UGT isoforms and human liver microsomes (HLMs) in the absence or presence of erlotinib and gefitinib"><entity charOffset="27-36" id="DDI-PubMed.19850672.s3.e0" text="erlotinib" /><entity charOffset="41-50" id="DDI-PubMed.19850672.s3.e1" text="gefitinib" /><entity charOffset="157-178" id="DDI-PubMed.19850672.s3.e2" text="4-methylumbelliferone" /><entity charOffset="180-184" id="DDI-PubMed.19850672.s3.e3" text="4-MU" /><entity charOffset="186-197" id="DDI-PubMed.19850672.s3.e4" text="glucuronide" /><entity charOffset="199-223" id="DDI-PubMed.19850672.s3.e5" text="imipramine N-glucuronide" /><entity charOffset="229-251" id="DDI-PubMed.19850672.s3.e6" text="bilirubin glucuronides" /><entity charOffset="353-362" id="DDI-PubMed.19850672.s3.e7" text="erlotinib" /><entity charOffset="367-376" id="DDI-PubMed.19850672.s3.e8" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e4" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e5" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e0" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e4" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e5" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e1" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e4" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e5" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e2" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e3" e2="DDI-PubMed.19850672.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e3" e2="DDI-PubMed.19850672.s3.e4" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e3" e2="DDI-PubMed.19850672.s3.e5" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e3" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e3" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e3" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e4" e2="DDI-PubMed.19850672.s3.e4" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e4" e2="DDI-PubMed.19850672.s3.e5" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e4" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e4" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e4" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e5" e2="DDI-PubMed.19850672.s3.e5" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e5" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e5" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e5" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e6" e2="DDI-PubMed.19850672.s3.e6" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e6" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e6" e2="DDI-PubMed.19850672.s3.e8" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e7" e2="DDI-PubMed.19850672.s3.e7" /><pair ddi="false" e1="DDI-PubMed.19850672.s3.e7" e2="DDI-PubMed.19850672.s3.e8" /></sentence><sentence text=" Inhibition kinetic studies were conducted" /><sentence text=" Area under the curve (AUC) ratios were used to predict the risk of potential DDI in vivo" /><sentence text=" Erlotinib exhibited selective potent competitive inhibition against 4-MU glucuronidation by UGT1A1, and gefitinib demonstrated a wide range of inhibition against UGT-mediated 4-MU glucuronidation, particularly against UGT1A1, UGT1A7, UGT1A9, and UGT2B7"><entity charOffset="1-10" id="DDI-PubMed.19850672.s6.e0" text="Erlotinib" /><entity charOffset="105-114" id="DDI-PubMed.19850672.s6.e1" text="gefitinib" /><entity charOffset="69-77" id="DDI-PubMed.19850672.s6.e2" text="4-MU" /><entity charOffset="176-184" id="DDI-PubMed.19850672.s6.e3" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e0" e2="DDI-PubMed.19850672.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e0" e2="DDI-PubMed.19850672.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e0" e2="DDI-PubMed.19850672.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e0" e2="DDI-PubMed.19850672.s6.e3" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e2" e2="DDI-PubMed.19850672.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e2" e2="DDI-PubMed.19850672.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e2" e2="DDI-PubMed.19850672.s6.e3" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e1" e2="DDI-PubMed.19850672.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19850672.s6.e1" e2="DDI-PubMed.19850672.s6.e3" /></sentence><sentence text=" Erlotinib also exerted potent mixed inhibition against bilirubin glucuronidation in HLMs"><entity charOffset="1-10" id="DDI-PubMed.19850672.s7.e0" text="Erlotinib" /><entity charOffset="56-65" id="DDI-PubMed.19850672.s7.e1" text="bilirubin" /><pair ddi="false" e1="DDI-PubMed.19850672.s7.e0" e2="DDI-PubMed.19850672.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19850672.s7.e0" e2="DDI-PubMed.19850672.s7.e1" /></sentence><sentence text=" We estimated that coadministration of erlotinib at 100 mg/day or higher doses may result in at least a 30% increase in the AUC of drugs predominantly cleared by UGT1A1"><entity charOffset="39-48" id="DDI-PubMed.19850672.s8.e0" text="erlotinib" /></sentence><sentence text=" Thus, the coadministration of erlotinib with drugs primarily cleared by UGT1A1 may result in potential DDI"><entity charOffset="31-40" id="DDI-PubMed.19850672.s9.e0" text="erlotinib" /></sentence><sentence text=" In contrast, gefitinib is unlikely to cause a clinically significant DDI through inhibition of glucuronidation"><entity charOffset="14-23" id="DDI-PubMed.19850672.s10.e0" text="gefitinib" /></sentence><sentence text="" /></document>